EverQuote just printed another strong quarter, and the business is cleaner than most small-cap internet names. Q1 2026 revenue grew 15% year over year to $190.9 million, adjusted EBITDA rose 30% to a record $29.3 million, and the company ended the quarter with $178.5 million in cash and no debt. For a stock with a …
# HYLN Stock Analysis: Real Catalyst, Real Execution Risk Hyliion finally has something better than a concept slide. Q1 2026 revenue came in at $2.8 million, up from $0.5 million a year ago, and the company just cleared non-recurring UL certification testing across the battery system, linear electric motor, and full KARNO Power Module. That …
If you want the short version, the best dividend stocks for 2026 are Realty Income (O), AbbVie (ABBV), and Chevron (CVX). They are not the highest-yield names on the screen, but that is the point. I would rather own a 3% to 6% yielder with real revenue, real balance-sheet support, and a visible 2026 catalyst …
PROK stock is one of those setups where the upside story is obvious and the holding-period pain is obvious too. ProKidney has a sub-$300 million market cap, roughly $271.7 million in cash from its last reported quarter, a Phase 3 kidney-disease program with FDA alignment on an accelerated path, and a stock that still trades …
The Tariff Problem Is Real. Here’s How to Play It. Every small-cap investor is asking the same question in May 2026: which companies actually survive the tariff cycle without getting clipped? The answer isn’t complicated. You find companies where revenue stays inside US borders — no Chinese supply chain, no export dependency, no “we’re monitoring …
Berkshire Hathaway just reported a record $397.4 billion in cash. The S&P 500 sits at 5,521, trading at a forward P/E of 20.9 — 28% above its 25-year average. And Warren Buffett called the current market a “casino.” We’re entering the weakest six-month stretch of the four-year presidential cycle. Here’s what the data says, what …
PBYI Stock Analysis: Puma Biotechnology Looks Cheap, but the Pipeline Still Has to Matter This PBYI stock analysis starts with the obvious part: Puma Biotechnology looks cheap on a screen. The company is profitable, it trades around 12x trailing earnings, it finished 2025 with $97.5 million in cash and marketable securities, and management is guiding …
Hudson Technologies is one of those small-cap stocks that sounds boring until you read the numbers and the regulations. That is why this HDSN stock analysis matters right now. Hudson sells and reclaims refrigerants, a niche business that benefits when the supply of virgin HFC refrigerants gets tighter under the AIM Act. At roughly a …
Alignment Healthcare reports Q1 2026 earnings after the bell today, April 30. The stock sits at $21.72 — roughly flat for the year. But the business has never grown this fast. Here are the numbers heading into tonight’s report, and where the actual risk lives. ## FY2025: The Growth Was Real $3.95 billion in revenue …
MTA at $6.62: Gold Royalty Without the Mining Risk Gold hit $4,700 an ounce this week. If you own a gold miner, you’re celebrating. You’re also exposed to diesel costs, labor disputes, equipment failures, and the fact that mining is genuinely hard. Metalla Royalty & Streaming (NYSE American: MTA) offers a cleaner trade. The company …